The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Sep 2021 16:00

RNS Number : 1660L
Silence Therapeutics PLC
08 September 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B9GTXM62

Issuer Name

SILENCE THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Societe Generale

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

01-Sep-2021

6. Date on which Issuer notified

02-Sep-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.990000

0.000000

4.990000

4485575

Position of previous notification (if applicable)

5.100000

0.000000

5.100000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BKKMKR23

4485575

4.990000

Sub Total 8.A

4485575

4.990000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

02-Sep-2021

13. Place Of Completion

London, United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWVSRAWUKRAR
Date   Source Headline
20th Sep 201712:02 pmRNSPrice Monitoring Extension
13th Sep 201712:07 pmRNSSecond Price Monitoring Extn
13th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 20171:30 pmRNSFurther Strengthens US Patent Estate
8th Sep 201712:07 pmRNSSecond Price Monitoring Extn
8th Sep 201712:02 pmRNSPrice Monitoring Extension
6th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
4th Sep 20177:00 amRNSNotice of Interim Results
23rd Aug 20177:00 amRNSSave the Date: Capital Markets Event 14 November
17th Aug 20174:05 pmRNSReplacement - Holding(s) in Company
17th Aug 20172:02 pmRNSDirector/PDMR Shareholding
15th Aug 20177:00 amRNSTwo further US patents to be granted
3rd Aug 20177:00 amRNSDirector/PDMR Shareholding
31st Jul 201711:43 amRNSDirector/PDMR Shareholding
31st Jul 20177:00 amRNSHolding(s) in Company
31st Jul 20177:00 amRNSUS patent to be granted
27th Jul 20172:43 pmRNSLicensee Quark Announces Positive AKI Results
24th Jul 20177:00 amRNSPresenting at Canaccord Genuity Growth Conference
24th Jul 20177:00 amRNSSilence Strengthens US Patent Estate
14th Jul 20177:00 amRNSCEO Ali Mortazavi appointed Chairman of Ultromics
10th Jul 20177:41 amRNSIP update
3rd Jul 20172:34 pmRNSIssue of claim in the UK High Courts
3rd Jul 20177:00 amRNSChange of Adviser
29th Jun 201711:47 amRNSHolding(s) in Company
6th Jun 20177:00 amRNSResult of AGM
1st Jun 20177:00 amRNSHiring of Chief Operating Officer
30th May 20177:00 amRNSSilence Continued Expansion of IP
16th May 20177:00 amRNSSignificant Expansion of Intellectual Property
4th May 201712:05 pmRNSNotice of AGM and Publication of Annual Report
3rd May 20177:00 amRNSSilence Therapeutics Presents New Data
12th Apr 20171:30 pmRNSAdditional Listing
3rd Apr 20177:00 amRNSGrant of Share Options to Directors
28th Mar 20177:00 amRNSPreliminary Results for the year to 31 Dec 2016
8th Mar 20177:00 amRNSNotice of Results
13th Jan 20172:03 pmRNSMinority Stake in Arrowhead Pharmaceuticals
9th Jan 20177:00 amRNSAcquisition of Minority Stake in Arrowhead
20th Dec 20167:00 amRNSSilence announces Quark arbitration resolution
15th Nov 20167:00 amRNSCRISPR/Cas9 Gene Editing Data
27th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSNotice of Results
5th Sep 20167:00 amRNSAppointment of CSO and Non-Executive Director
18th Jul 20167:00 amRNSDirector/PDMR Shareholding
17th Jun 20163:48 pmRNSResult of AGM
1st Jun 20162:35 pmRNSHolding(s) in Company
24th May 20167:00 amRNSBoard Changes, Advisory Board and Notice of AGM
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
18th Apr 20166:09 pmRNSDirector/PDMR Shareholding
18th Apr 20167:00 amRNSGrant of share options to Chief Executive
5th Apr 20167:00 amRNSAtu027 Update
5th Apr 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.